Meta-Analysis of Microarray Data Identifies GAS6 Expression as an Independent Predictor of Poor Survival in Ovarian Cancer
Figure 2
GAS6 expression level in relation to various clinicopathological parameters. (a) Ovarian cancers from patients with residual disease have significantly higher level of GAS6 expression. (b) Ovarian cancers from TMN T4 patients tended to have higher expression of GAS6. (c) GAS6 expression was similar across clear cell, endometrioid, serous, and transitional cell ovarian cancers as assessed by immunohistochemistry on tissue microarray. CICOC: clear cell ovarian cancer; EnOC: endometrioid ovarian cancer; SOC: serous ovarian cancer; TCOC: transitional cell ovarian cancer.
